196 reports of this reaction
2.0% of all TASIMELTEON reports
#10 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT DECREASED is the #10 most commonly reported adverse reaction for TASIMELTEON, manufactured by Vanda Pharmaceuticals Inc.. There are 196 FDA adverse event reports linking TASIMELTEON to THERAPEUTIC PRODUCT EFFECT DECREASED. This represents approximately 2.0% of all 9,924 adverse event reports for this drug.
Patients taking TASIMELTEON who experience therapeutic product effect decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT DECREASED is a less commonly reported adverse event for TASIMELTEON, but still significant enough to appear in the safety profile.
In addition to therapeutic product effect decreased, the following adverse reactions have been reported for TASIMELTEON:
The following drugs have also been linked to therapeutic product effect decreased in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT DECREASED has been reported as an adverse event in 196 FDA reports for TASIMELTEON. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT DECREASED accounts for approximately 2.0% of all adverse event reports for TASIMELTEON, making it a notable side effect.
If you experience therapeutic product effect decreased while taking TASIMELTEON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.